The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
B | Blood and blood forming organs | |
2
|
B02 | Antihemorrhagics | |
3
|
B02B | Vitamin K and other hemostatics | |
4
|
B02BX | Other systemic hemostatics | |
5
|
B02BX09 |
| Active Ingredient |
|---|
|
Fostamatinib mediates its activity effectively through its major metabolite, R406, which is a tyrosine kinase inhibitor with demonstrated activity against spleen tyrosine kinase (SYK). R406 inhibits signal transduction of B-cell receptors and Fc-activating receptors, which play a key role in antibody-mediated cellular responses. The fostamatinib metabolite R406 reduces antibody-mediated destruction of platelets. |
| Document | Type | Information Source | |
|---|---|---|---|
| TAVALISSE Film-coated tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| TAVLESSE Film-coated tablet | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.